• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验中克罗恩病患者体重增加:一个产生假说的时间趋势分析。

The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis.

机构信息

Department of Medicine, Inflammatory Bowel Disease Clinic and Alberta IBD Consortium, University of Calgary, Calgary, AB, Canada.

出版信息

Inflamm Bowel Dis. 2013 Dec;19(13):2949-56. doi: 10.1097/MIB.0b013e31829936a4.

DOI:10.1097/MIB.0b013e31829936a4
PMID:23945182
Abstract

BACKGROUND

The incidence of obesity is increasing worldwide. Recent evidence shows that the incidence of Crohn's disease (CD) is increasing as well. Adipocytes release a variety of proinflammatory cytokines and peptides. Visceral adiposity may play an important role in the initiation and perpetuation of inflammation in CD. We report on an analysis of body weight in CD clinical trials between 1991 and 2008.

METHODS

MEDLINE-based databases were searched for randomized controlled trials pertaining to CD. A time-trend analysis was carried out to investigate changes in weight and disease activity over time. Potential correlation between subject weight and clinical activity was studied.

RESULTS

Forty randomized controlled trials involving a total of 10,282 patients with CD conducted between 1991 and 2008 were included. No significant change in gender distribution was noted throughout the follow-up. A significant increase in weight (r = 0.360; 95% confidence interval [CI]: 0.4556-0.8813) and body mass index (r = 0.1431; 95% CI: 0.02628-0.2272) was observed over the time period. Study subjects demonstrated a significant increase in clinical disease activity as measured by the Crohn's disease activity index (r = 0.1092; 95% CI: 2.101-9.087) and disease duration (r = 0.06340; 95% CI: 0.02421-0.2530) over the same time period.

CONCLUSIONS

We demonstrate increasing body weight over time from 1991 to 2008 in CD as evidenced by baseline data from randomized clinical trials. Adiposity may play a potential role in initiating and perpetuating intestinal inflammation, a hypothesis that should be explored further.

摘要

背景

肥胖的发病率在全球范围内呈上升趋势。最近的证据表明,克罗恩病(CD)的发病率也在上升。脂肪细胞释放多种促炎细胞因子和肽。内脏肥胖可能在 CD 炎症的启动和持续中起重要作用。我们报告了 1991 年至 2008 年期间 CD 临床试验中体重的分析结果。

方法

基于 MEDLINE 的数据库搜索了与 CD 相关的随机对照试验。进行时间趋势分析,以调查体重和疾病活动随时间的变化。研究了受试者体重与临床活动之间的潜在相关性。

结果

纳入了 1991 年至 2008 年间进行的 40 项涉及 10282 例 CD 患者的随机对照试验。在整个随访过程中,性别分布没有明显变化。体重(r = 0.360;95%置信区间[CI]:0.4556-0.8813)和体重指数(r = 0.1431;95%CI:0.02628-0.2272)呈显著增加。研究对象的临床疾病活动也显著增加,如克罗恩病活动指数(r = 0.1092;95%CI:2.101-9.087)和疾病持续时间(r = 0.06340;95%CI:0.02421-0.2530)。

结论

我们证明了从 1991 年到 2008 年 CD 患者的体重随着时间的推移而增加,这是基于随机临床试验的基线数据。肥胖可能在启动和持续肠道炎症中发挥潜在作用,这一假设需要进一步探讨。

相似文献

1
The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis.临床试验中克罗恩病患者体重增加:一个产生假说的时间趋势分析。
Inflamm Bowel Dis. 2013 Dec;19(13):2949-56. doi: 10.1097/MIB.0b013e31829936a4.
2
Environment and risk of Crohn's disease: comments on "the increasing weight of Crohn's disease subjects in clinical trials".环境与克罗恩病风险:对“临床试验中克罗恩病受试者体重增加”的评论
Inflamm Bowel Dis. 2014 Apr;20(4):E11-2. doi: 10.1097/MIB.0000000000000005.
3
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.基于 SONIC 数据的事后分析验证克罗恩病患者内镜活动评分的有效性。
Gastroenterology. 2013 Nov;145(5):978-986.e5. doi: 10.1053/j.gastro.2013.08.010. Epub 2013 Aug 14.
4
Nonbloody Diarrhea but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulcerative Colitis.非血性腹泻但诊断时无明显体重减轻与溃疡性结肠炎回肠储袋肛管吻合术后新发克罗恩病的发生相关。
Inflamm Bowel Dis. 2016 Mar;22(3):654-61. doi: 10.1097/MIB.0000000000000630.
5
Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease?内脏脂肪细胞:肥胖症中的老演员还是克罗恩病中的新主角?
Gut. 2012 Jan;61(1):86-94. doi: 10.1136/gutjnl-2011-300391. Epub 2011 Sep 19.
6
A comprehensive review and update on Crohn's disease.克罗恩病的全面综述与更新
Dis Mon. 2018 Feb;64(2):20-57. doi: 10.1016/j.disamonth.2017.07.001. Epub 2017 Aug 18.
7
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.克罗恩病的回结肠镜评分的部位和中心读数的一致性:EXTEND 试验数据比较。
Gastrointest Endosc. 2016 Jan;83(1):188-97.e1-3. doi: 10.1016/j.gie.2015.06.018. Epub 2015 Jul 30.
8
Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.克罗恩病和溃疡性结肠炎。欧洲一项基于人群的起始队列研究中疾病第一年的发病率、病程及预后
Dan Med J. 2014 Jan;61(1):B4778.
9
Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease.克罗恩病患者接受英夫利昔单抗治疗后体重指数与临床结局的关系
J Crohns Colitis. 2016 Oct;10(10):1144-50. doi: 10.1093/ecco-jcc/jjw079. Epub 2016 Mar 19.
10
Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease.肥胖的克罗恩病患者常有肠道外表现。
Inflamm Bowel Dis. 2017 Sep;23(9):1637-1642. doi: 10.1097/MIB.0000000000001187.

引用本文的文献

1
Heavy arch: from inflammatory bowel diseases to metabolic disorders.重拱:从炎症性肠病到代谢紊乱。
Gut. 2024 Jul 11;73(8):1376-1387. doi: 10.1136/gutjnl-2024-331914.
2
Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease.营养、营养状况、微量营养素缺乏与炎症性肠病的疾病进程。
Nutrients. 2023 Aug 31;15(17):3824. doi: 10.3390/nu15173824.
3
The Bidirectional Link between Nutritional Factors and Inflammatory Bowel Diseases: Dietary Deficits, Habits, and Recommended Interventions-A Narrative Review.
营养因素与炎症性肠病之间的双向联系:饮食不足、习惯及推荐干预措施——一篇叙述性综述
Foods. 2023 May 14;12(10):1987. doi: 10.3390/foods12101987.
4
GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use.GLP-1 受体激动剂在炎症性肠病肥胖患者中的应用:从分子机制到临床考虑因素,以及安全有效使用的实用建议。
Curr Obes Rep. 2023 Jun;12(2):61-74. doi: 10.1007/s13679-023-00506-3. Epub 2023 Apr 21.
5
Obesity and novel management of inflammatory bowel disease.肥胖与炎症性肠病的新治疗策略。
World J Gastroenterol. 2023 Mar 28;29(12):1779-1794. doi: 10.3748/wjg.v29.i12.1779.
6
High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend.炎症性肠病中肥胖负担高且体重减轻药物治疗率低:10年趋势
Crohns Colitis 360. 2023 Mar 8;5(2):otad007. doi: 10.1093/crocol/otad007. eCollection 2023 Apr.
7
Changing Patterns of Relationships Between Geographic Markers and IBD: Possible Intrusion of Obesity.地理标志物与炎症性肠病之间关系模式的变化:肥胖可能的影响
Crohns Colitis 360. 2020 Jun 3;2(2):otaa044. doi: 10.1093/crocol/otaa044. eCollection 2020 Apr.
8
Prevalence and Impact of Obesity in a Population-Based Cohort of Patients With Crohn's Disease.基于人群的克罗恩病患者队列中肥胖的流行率和影响。
J Clin Gastroenterol. 2024 Feb 1;58(2):176-182. doi: 10.1097/MCG.0000000000001821.
9
Impact of tumor necrosis factor antagonist combination and anti-integrin therapies on body mass index in inflammatory bowel disease: A cross-sectional study.肿瘤坏死因子拮抗剂联合治疗及抗整合素疗法对炎症性肠病患者体重指数的影响:一项横断面研究
Front Med (Lausanne). 2023 Jan 6;9:1045661. doi: 10.3389/fmed.2022.1045661. eCollection 2022.
10
The Role of Gut Microbiota and Metabolites in Obesity-Associated Chronic Gastrointestinal Disorders.肠道微生物群及其代谢物在肥胖相关慢性胃肠道疾病中的作用。
Nutrients. 2022 Jan 31;14(3):624. doi: 10.3390/nu14030624.